NEW YORK (GenomeWeb News) – Johnson & Johnson’s drug research division has licensed Simcyp’s drug modeling and simulation platform, the UK-based firm said today.
Through the license, Johnson & Johnson Pharmaceutical Research and Development will provide access to Simcyp’s population-based Simulator and pediatric module to its global R&D teams for a period of three years. The Simcyp platform provides modeling and simulation of drug absorption, distribution, metabolism, and elimination in virtual populations.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.